Genaera Reaches Target Enrollment in Two Phase II Studies for Squalamine

Genaera has reached the target enrollment for two of three Phase II studies in "wet" age-related macular degeneration (AMD).

The company enrolled 45 patients in a multicenter, randomized, masked, controlled, U.S. Phase II clinical trial (MSI-1256F-208) with squalamine for the treatment of choroidal neovascularization associated with AMD.

The company also announced that it had completed enrollment in a multicenter, open-label U.S. pharmacokinetics and safety Phase II clinical trial (MSI-1256F-207). Squalamine is the leading systemically delivered anti-angiogenic drug being developed to treat AMD. Enrollment in the MSI-1256F-208 trial will continue through February 2005 in order to accept patients still in screening.